Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,longTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,dividendDate,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,KDNY,211506000.0,44616300,,,-37215000,,-37215000,9543000,-25346000,-35309000,-35309000,,,,,,0,351000,35660000,25697000,-1906000,,-37215000,-37215000,66572000.0,466494000.0,98254000.0,300519000.0,1175000.0,398773000.0,4000.0,-166044000.0,35304000.0,22441000.0,65000.0,6481000.0,168092000.0,24984000.0,65000.0,74280000.0,226000000.0,2999000.0,51478000.0,273000.0,7363000.0,,,8161000.0,3719000.0,7834000.0,580000.0,-1423000.0,580000.0,-19658000.0,9000.0,-28081000.0,1224000.0,6000.0,5608000.0,-594000.0,,,,201016000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1601596800,-0.5162289,13.32 - 13.78,0.0,0.0,13.56,18,12,finmb_634057733,NasdaqGS,"Chinook Therapeutics, Inc.",USD,321932,580928,2.54,0.23196347,10.95 - 21.68,-8.190001,-0.37776753,10.95,21.68,1617811500,1635969600,1636401600,USD,PRE,13.49,1630526403,-0.07000065,13.6,13.78,13.32,232562,us_market,2,0,-0.12432059,"Chinook Therapeutics, Inc.",NMS,-3.52,-3.8323863,13.075571,0.4144287,0.031694885,15.405181,-1.9151812,601873856,15,America/New_York,EDT,-14400000,False,False,,,,21.68,10.95,13.08,15.41,321.93k,580.93k,44.62M,,20.95M,10.38%,70.63%,1.16M,5.53,4.53%,2.59%,1.04M,,,,,,0.00%,"Oct 01, 2020",,1:5,"Oct 01, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-6,516.72%",-22.59%,-76.26%,1.18M,0.05,,-33.47M,-74.21M,-113.69M,,,219.57M,4.92,41.1M,13.68,9.05,,-80.44M,-26.02M,Value,98102,Healthcare,105,"Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",Seattle,206 485 7051,WA,1609372800,United States,http://www.chinooktx.com,86400,1600 Fairview Avenue East,Biotechnology,Suite 100
t-1,KDNY,245190000.0,44616300,-2464500.0,,-35366500,,-34365000,2375500,-16732500,-16854500,-16854500,,-2500.0,,,,-1001500,413500,17268000,17146000,-18512000,,-34365000,-34365000,66991000.0,463436000.0,94380000.0,334622000.0,1205000.0,429002000.0,4000.0,-128829000.0,32862000.0,22441000.0,11000.0,6190000.0,187750000.0,22809000.0,11000.0,76299000.0,254081000.0,3000000.0,59622000.0,262000.0,3995000.0,,,17705000.0,-687000.0,55036000.0,54921500.0,-5838000.0,54929500.0,85726000.0,89500.0,-24321000.0,626000.0,409000.0,15534000.0,-198500.0,-8000.0,37454500.0,-10500.0,231272000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1601596800,-0.5162289,13.32 - 13.78,0.0,0.0,13.56,18,12,finmb_634057733,NasdaqGS,"Chinook Therapeutics, Inc.",USD,321932,580928,2.54,0.23196347,10.95 - 21.68,-8.190001,-0.37776753,10.95,21.68,1617811500,1635969600,1636401600,USD,PRE,13.49,1630526403,-0.07000065,13.6,13.78,13.32,232562,us_market,2,0,-0.12432059,"Chinook Therapeutics, Inc.",NMS,-3.52,-3.8323863,13.075571,0.4144287,0.031694885,15.405181,-1.9151812,601873856,15,America/New_York,EDT,-14400000,False,False,,,,21.68,10.95,13.08,15.41,321.93k,580.93k,44.62M,,20.95M,10.38%,70.63%,1.16M,5.53,4.53%,2.59%,1.04M,,,,,,0.00%,"Oct 01, 2020",,1:5,"Oct 01, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-6,516.72%",-22.59%,-76.26%,1.18M,0.05,,-33.47M,-74.21M,-113.69M,,,219.57M,4.92,41.1M,13.68,9.05,,-80.44M,-26.02M,Value,98102,Healthcare,105,"Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",Seattle,206 485 7051,WA,1609372800,United States,http://www.chinooktx.com,86400,1600 Fairview Avenue East,Biotechnology,Suite 100
t-2,KDNY,245190000.0,44616300,-2464500.0,,-35366500,,-34365000,2375500,-16732500,-16854500,-16854500,,-2500.0,,,,-1001500,413500,17268000,17146000,-18512000,,-34365000,-34365000,66991000.0,463436000.0,94380000.0,334622000.0,1205000.0,429002000.0,4000.0,-128829000.0,32862000.0,22441000.0,11000.0,6190000.0,187750000.0,22809000.0,11000.0,76299000.0,254081000.0,3000000.0,59622000.0,262000.0,3995000.0,,,17705000.0,-687000.0,55036000.0,54921500.0,-5838000.0,54929500.0,85726000.0,89500.0,-24321000.0,626000.0,409000.0,15534000.0,-198500.0,-8000.0,37454500.0,-10500.0,231272000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1601596800,-0.5162289,13.32 - 13.78,0.0,0.0,13.56,18,12,finmb_634057733,NasdaqGS,"Chinook Therapeutics, Inc.",USD,321932,580928,2.54,0.23196347,10.95 - 21.68,-8.190001,-0.37776753,10.95,21.68,1617811500,1635969600,1636401600,USD,PRE,13.49,1630526403,-0.07000065,13.6,13.78,13.32,232562,us_market,2,0,-0.12432059,"Chinook Therapeutics, Inc.",NMS,-3.52,-3.8323863,13.075571,0.4144287,0.031694885,15.405181,-1.9151812,601873856,15,America/New_York,EDT,-14400000,False,False,,,,21.68,10.95,13.08,15.41,321.93k,580.93k,44.62M,,20.95M,10.38%,70.63%,1.16M,5.53,4.53%,2.59%,1.04M,,,,,,0.00%,"Oct 01, 2020",,1:5,"Oct 01, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-6,516.72%",-22.59%,-76.26%,1.18M,0.05,,-33.47M,-74.21M,-113.69M,,,219.57M,4.92,41.1M,13.68,9.05,,-80.44M,-26.02M,Value,98102,Healthcare,105,"Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",Seattle,206 485 7051,WA,1609372800,United States,http://www.chinooktx.com,86400,1600 Fairview Avenue East,Biotechnology,Suite 100
t-3,KDNY,-53777000.0,44616300,3870000.0,,-7743000,,-7743000,3879000,0,-7749000,-7749000,,-4000.0,,,,0,0,7749000,0,6000,,-7743000,-7743000,,6493000.0,31792000.0,-53777000.0,107000.0,22052000.0,2000.0,-60099000.0,,,-173000.0,,17901000.0,5991000.0,-173000.0,3077000.0,18975000.0,,,,2228000.0,147000.0,24179000.0,17705000.0,1493000.0,-378000.0,-18000.0,2099000.0,54929500.0,-4075000.0,39000.0,-3718000.0,77000.0,409000.0,356000.0,-378000.0,-18000.0,37454500.0,-10500.0,12984000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1601596800,-0.5162289,13.32 - 13.78,0.0,0.0,13.56,18,12,finmb_634057733,NasdaqGS,"Chinook Therapeutics, Inc.",USD,321932,580928,2.54,0.23196347,10.95 - 21.68,-8.190001,-0.37776753,10.95,21.68,1617811500,1635969600,1636401600,USD,PRE,13.49,1630526403,-0.07000065,13.6,13.78,13.32,232562,us_market,2,0,-0.12432059,"Chinook Therapeutics, Inc.",NMS,-3.52,-3.8323863,13.075571,0.4144287,0.031694885,15.405181,-1.9151812,601873856,15,America/New_York,EDT,-14400000,False,False,,,,21.68,10.95,13.08,15.41,321.93k,580.93k,44.62M,,20.95M,10.38%,70.63%,1.16M,5.53,4.53%,2.59%,1.04M,,,,,,0.00%,"Oct 01, 2020",,1:5,"Oct 01, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-6,516.72%",-22.59%,-76.26%,1.18M,0.05,,-33.47M,-74.21M,-113.69M,,,219.57M,4.92,41.1M,13.68,9.05,,-80.44M,-26.02M,Value,98102,Healthcare,105,"Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",Seattle,206 485 7051,WA,1609372800,United States,http://www.chinooktx.com,86400,1600 Fairview Avenue East,Biotechnology,Suite 100
